Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon in essential thrombocythaemia.

H Gisslinger1, A Chott, W Scheithauer

  • 1Second Department of Medicine, University of Vienna, Austria.

British Journal of Haematology
|October 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.

Leukemia·2017
Same author

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Leukemia·2017
Same author

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

Leukemia·2017
Same author

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Leukemia·2017
Same author

Response to Harrison et al. 'Clinically relevant differences between BCSH and WHO diagnostic criteria for ET'.

Leukemia·2016
Same author

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Leukemia·2016

Recombinant interferon alfa-2c effectively treats essential thrombocythemia (ET) symptoms for up to four years. Continued treatment is recommended as symptoms return after stopping interferon therapy.

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by elevated platelet counts.
  • Long-term management of symptomatic ET requires effective and well-tolerated therapies.

Purpose of the Study:

  • To evaluate the efficacy and safety of recombinant interferon alfa-2c (IFN) in the long-term treatment of patients with essential thrombocythemia.
  • To assess the impact of IFN on hematological parameters, clinical symptoms, and bone marrow morphology.

Main Methods:

  • A cohort of 20 patients with ET received subcutaneous recombinant interferon alfa-2c for up to 4 years.
  • Dosage was adjusted based on individual tolerance and response, with a median dose reduction over time.
  • Hematological parameters, clinical symptoms, bone marrow biopsies, and side effects were monitored.

Related Experiment Videos

Main Results:

  • 65% of patients achieved complete remission and 20% partial remission.
  • Platelet counts remained stable during treatment despite dose reductions, but increased upon withdrawal.
  • Significant decrease in white blood cells and megakaryocytes observed; clinical symptoms improved during treatment.

Conclusions:

  • Recombinant interferon alfa-2c is an effective and well-tolerated long-term treatment option for symptomatic ET.
  • Continued therapy is advised due to the recurrence of thrombocytosis after IFN withdrawal.
  • Potential side effects include initial flu-like symptoms and late-onset thyroid autoimmunity.